Anxiolytics
Pharmacology & Therapeutics-II — Section 1(b), part 1
Definition
Anxiolytics (antianxiety drugs, “minor tranquillizers”) are drugs used to control the symptoms of anxiety and
produce a restful state of mind without interfering with normal mental or physical functioning.
Classification
• Benzodiazepines — Diazepam, Chlordiazepoxide, Oxazepam, Lorazepam, Alprazolam
• Azapirones — Buspirone
• Sedative antihistamines — Hydroxyzine
• β-blockers — Propranolol
• Antidepressants — SSRIs and SNRIs, for chronic/severe anxiety disorders
1. Benzodiazepines
BZDs are the most widely used anxiolytics due to their high therapeutic index. They facilitate GABAergic
transmission in the limbic system (governing thought and mood) and the midbrain reticular formation
(governing wakefulness). At hypnotic/anxiolytic doses they do not significantly affect respiration or
cardiovascular function — the same class-level advantages already established under Sedatives & Hypnotics.
Diazepam is the prototype and is already covered in full in the Sedatives & Hypnotics notes — no separate
study needed. The remaining BZDs differ only in onset/duration and niche use:
• Chlordiazepoxide — the first BZD; slow, smooth, long-lasting effect; used for chronic anxiety and alcohol
withdrawal.
• Oxazepam — no active metabolites; preferred in the elderly or in liver disease.
• Lorazepam — short half-life, no active metabolites, strong amnesic effect; used for short anxiety states
and panic.
• Alprazolam — high potency with mood-elevating property; useful when anxiety coexists with depression
or panic disorder.
Adverse effects: Sedation, psychomotor/cognitive impairment, confusional states (especially in the elderly),
and dependence with prolonged use.
2. Buspirone
A newer anxiolytic, chemically and pharmacologically distinct from the benzodiazepines.
• Mechanism: selective partial agonist at 5-HT ₁ᴀ receptors (not GABA-A — an entirely different target
from BZDs).
• Advantages: no significant sedation or cognitive impairment; no muscle relaxant or anticonvulsant action;
does not cause tolerance or physical dependence.
• Limitations: ineffective in severe anxiety, panic attacks, or OCD; slow onset, taking up to 2 weeks for
effect.
Pharmacology & Therapeutics-II — Section 1(b), part 1
Definition
Anxiolytics (antianxiety drugs, “minor tranquillizers”) are drugs used to control the symptoms of anxiety and
produce a restful state of mind without interfering with normal mental or physical functioning.
Classification
• Benzodiazepines — Diazepam, Chlordiazepoxide, Oxazepam, Lorazepam, Alprazolam
• Azapirones — Buspirone
• Sedative antihistamines — Hydroxyzine
• β-blockers — Propranolol
• Antidepressants — SSRIs and SNRIs, for chronic/severe anxiety disorders
1. Benzodiazepines
BZDs are the most widely used anxiolytics due to their high therapeutic index. They facilitate GABAergic
transmission in the limbic system (governing thought and mood) and the midbrain reticular formation
(governing wakefulness). At hypnotic/anxiolytic doses they do not significantly affect respiration or
cardiovascular function — the same class-level advantages already established under Sedatives & Hypnotics.
Diazepam is the prototype and is already covered in full in the Sedatives & Hypnotics notes — no separate
study needed. The remaining BZDs differ only in onset/duration and niche use:
• Chlordiazepoxide — the first BZD; slow, smooth, long-lasting effect; used for chronic anxiety and alcohol
withdrawal.
• Oxazepam — no active metabolites; preferred in the elderly or in liver disease.
• Lorazepam — short half-life, no active metabolites, strong amnesic effect; used for short anxiety states
and panic.
• Alprazolam — high potency with mood-elevating property; useful when anxiety coexists with depression
or panic disorder.
Adverse effects: Sedation, psychomotor/cognitive impairment, confusional states (especially in the elderly),
and dependence with prolonged use.
2. Buspirone
A newer anxiolytic, chemically and pharmacologically distinct from the benzodiazepines.
• Mechanism: selective partial agonist at 5-HT ₁ᴀ receptors (not GABA-A — an entirely different target
from BZDs).
• Advantages: no significant sedation or cognitive impairment; no muscle relaxant or anticonvulsant action;
does not cause tolerance or physical dependence.
• Limitations: ineffective in severe anxiety, panic attacks, or OCD; slow onset, taking up to 2 weeks for
effect.